Targeted therapies and the use of molecular profiling to determine which first-line treatments patients should receive have rapidly found their feet in the non-small cell lung cancer (NSCLC) market. Even the segmentation of this market into very small patient sub-populations – such as the EML4-ALK positive group, which accounts for between just 3-7 percent of all NCSLC patients – can prove commercially enticing as pharma companies carve out their own niches.
